These international actions broaden an existing legal front in New Jersey, where Arbutus continues to pursue claims regarding five U.S. patents. The company alleges that Pfizer and BioNTech improperly utilized its proprietary lipid nanoparticle delivery method to develop their high-profile vaccines.
In section Market Quotes
Arbutus Expands Patent Battle Over COVID-19 Vaccine Technology
Arbutus Biopharma and its licensee Genevant have launched three new patent infringement lawsuits against Pfizer and BioNTech, targeting the lipid nanoparticle technology used in their COVID-19 vaccines. The legal filings, submitted in Canada and the Unified Patent Court, seek both monetary damages and formal injunctions to block further use of the contested delivery system.
Simultaneously, Arbutus has resolved its separate litigation with Moderna. The company confirmed it received $178 million earlier this month as part of a settlement agreement. Following this influx of capital, Arbutus plans to initiate a shareholder return program in the third quarter, authorizing common share repurchases of up to $230 million.
Comments (0)
No comments yet. Be the first!